This Trial is Conducted in the United State of America. The Aim of This Trial is to Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity

Trial Profile

This Trial is Conducted in the United State of America. The Aim of This Trial is to Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs NN 9277 (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 04 Aug 2017 Planned End Date changed from 6 Sep 2017 to 25 Oct 2017.
    • 04 Aug 2017 Planned primary completion date changed from 6 Sep 2017 to 25 Oct 2017.
    • 16 Nov 2016 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top